Medtronic plc stock (IE00BTN1Y115): investors focus on upcoming Q4 earnings and restructuring

Medtronic shares on the NYSE were broadly stable on 06/02/2026 as investors in the United States positioned ahead of the medical technology group’s fourth-quarter earnings report due on 06/03/2026, with markets balancing expectations for a year-over-year earnings decline against guidance for continued revenue growth, according to a preview from GuruFocus as of 06/02/2026.

The company, which is headquartered in Dublin but primarily listed in the United States on the NYSE under the ticker MDT, is expected to show a 4.3% year-on-year drop in quarterly earnings alongside modest top-line expansion when it reports on 06/03/2026, while the stock last closed around USD 73.95 on 06/02/2026 in New York, according to pricing data from MarketBeat as of 06/02/2026.

The stock traded at approximately USD 73.95 on 06/02/2026 on the NYSE, compared with about USD 96.13 at the beginning of 2026, indicating a double-digit percentage decline over the period as reported by MarketBeat as of 06/02/2026.

As of: 03/06/2026

By the editorial team - specialized in equity coverage.

Medtronic plc: core business model

Medtronic generates revenue by developing and selling a broad range of implantable devices, surgical equipment and disease-management technologies that hospitals and physicians use to treat chronic cardiovascular, neurological and metabolic conditions worldwide.

Medtronic plc in peer comparison

In the global medical technology space, Medtronic competes with large diversified peers such as Abbott Laboratories and Boston Scientific, which also focus on cardiovascular and other interventional therapies and are likewise listed in the United States.

According to MarketBeat as of 06/02/2026, Medtronic’s share price around USD 73.95 places it below the levels seen for some peers in 2026 when measured against their respective starting points for the year, reflecting differing investor views on growth, margin profiles and the impact of ongoing portfolio changes across the sector.

Conclusion

With the fourth-quarter earnings report scheduled for 06/03/2026 and expectations pointing to lower profit but higher revenue, Medtronic’s near-term share-price path will likely be shaped by how the actual numbers compare with forecasts and by any updated commentary on its restructuring efforts.

In comparison with key United States-listed peers in the medical technology industry, investors are monitoring whether Medtronic’s combination of scale, portfolio adjustments and growth initiatives is sufficient to close the performance gap that has emerged in 2026.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.